Voice biomarkers as game-changer in improving patient outcomes and reducing costs.
Voice biomarkers as game-changer in improving patient outcomes and reducing costs.
How our SaaS Platform for Voice Analysis works
We provide AI-driven technology to extract digital biomarkers from voice samples
Created in Germany
ISO-certified Infrastructure
Following ISO 13485
Why choose our Voice Biomarkers Technology?
Reliability & Accuracy
80%+ accuracy evaluated in ongoing clinical trials
High Accessibility
Voice data easily collected with smartphones
Scalability
Across languages, markets and indications
Non-invasive and cost-effective
Monitoring instrument
Data Protection
Through anonymization of patient data, encryption and secure storage
Regulatory Independence
From country-specific regulations
Currently, we focus on two applications in respiratory diseases and cardiology
- the biggest causes of hospitalization worldwide.
Vocal Biomarkers in Heart Failure
- Heart’s inability to pump efficiently causes lung fluid retention that leads to voice alterations.
- Vocal biomarkers for detecting heart failure severity state and early prediction of heart decompensation.
- Novel data sets collected in clinical studies.
- Dedicated patient companion app developed by Zana with patients.
Vocal Biomarkers in Respiratory Diseases
- Voice changes are highly correlated with altered lung function in patients with asthma and COPD (Chronic obstructive pulmonary disease).
- Vocal biomarkers for early prediction of shortness of breath and declining lung function.
- Novel and tailored data sets collected in clinical studies.
- Customized patient app for real-world data collection developed by Zana.
Our goal is to democratize the digital biomarkers market
Zana AI platform is designed to integrate biomarkers and speech analysis tools developed by other industry players - growing into a go-to place for digital biomarker services for various indications.